Outlook Therapeutics, Inc. OTLK
NASDAQ · United States · Health Technology
$0.5750+0.00 (+0.26%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. W
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.